鼻咽癌患者血清胸苷激酶1的表达及临床意义  

Expresson and significiance of serum thymidine kinase in patients with nasopharyngeal carcinoma

作　　者：姚怡敏[1] 周菊英[1] 俞志英[1] 徐晓婷[1] 秦颂兵[1] 吴琼[1] 赵奇[1] 许愿[1] 

机构地区：[1]苏州大学附属第一医院放疗科,江苏省215006

出　　处：《江苏医药》2012年第3期300-303,共4页Jiangsu Medical Journal

摘　　要：目的探讨血清胸苷激酶1(STK1)水平变化在鼻咽癌诊断和疗效评估中的意义。方法采用ECL点印迹免疫-增强化学发光法检测28例鼻咽癌患者(A组)放疗前后的血清STK1水平,结果与49名健康体检者(B组)比较。结果 A组患者放疗前血清STK1水平为(1.93±0.63)pmol/L,显著高于放疗后的(1.58±0.40)pmol/L和B组的(1.36±0.86)pmol/L(P<0.05)。A组放疗前STK1阳性率显著高于放疗后和B组(39.13%vs.9.52%和10.20%)(P<0.05)。结论检测STK1对于鼻咽癌患者的筛检、诊断、治疗效果评估等有重要参考价值。Objective To investigate the significiance of detecting surum thymidine kinase 1（STK1） in diagnosis and evaluation of treatment efficacy of nasopharyngeal carcinoma.Methods The expresson of STK1 was detected with sensitive chemiluminescence dot-blot assay in 28 patients with nasopharyngeal carcinoma（group A） before and after radiotherapy and 49 healthy people（group B）.Results STK1 levels were higher in group A before radiotherapy than those in group A after radiotherapy and group B [（1.93±0.63） pmol/L vs.（1.58±0.40） pmol/L and（1.36±0.86） pmol/L]（P0.05）.So did the positive rate of STK1（39.13% vs.9.52% and 10.20%）（P0.05）.Conclusion The detection of STK1 is valuable in the diagnosis and evaluation of treatment efficacy of nasopharyngeal carcinoma.

关 键 词：胸苷激酶1 鼻咽癌 

分 类 号：R730[医药卫生—肿瘤]